Expanding Portfolio Immunostics offers a diverse range of diagnostic solutions across oncology, women's health, infectious disease, respiratory conditions, and toxicology, positioning them as a versatile supplier for healthcare providers seeking comprehensive diagnostic tools.

Recent Product Launch The successful launch of the AFIAS COVID-19 antibody test during March 2020 indicates the company's capability to rapidly develop and deploy relevant diagnostic products, presenting opportunities for expanding their COVID-19 testing range and related diagnostic assays.

Global Engagement Participation in Medlab Middle East 2023 showcases Immunostics' active efforts to engage with international markets, which could open avenues for strategic partnerships and new sales channels in the Middle East and beyond.

Acquisition Backing Being acquired by Boditech Med Inc. since 2016 highlights a solid backing and potential for enhanced research, development, and distribution capabilities, making Immunostics a reliable partner for distributors seeking innovative diagnostic solutions.

Market Opportunity With a revenue range of $1 million to $10 million and a focused product portfolio, Immunostics represents an attractive growth opportunity for sales teams targeting mid-sized diagnostics companies with expanding healthcare needs.